Increasing Prevalence in Emerging Economies to Benefit Demand for HPV, CMV Therapeutics, says TMR

The global market for HPV and CMV therapeutics features numerous healthcare industry giants such as Roche AG, Valeant Pharmaceuticals, AbbVie Inc., Fresenius Kabi USA, Perrigo Company plc, Actavis plc, Fougera Pharmaceuticals, and Merck & Co. According to Transparency Market Research, Valeant Pharmaceuticals, Fougera Pharmaceuticals, and Perrigo Company plc held a dominant 89.2% share in the global HPV therapeutics market in 2013, while the leaders in the CMV therapeutics market were Roche AG, Clinigen Group plc, and Fresenius Kabi USA, who collectively accounted for 93% of the market.

The key opportunity for manufacturers of HPV and CMV therapeutics is the development of biologics and drugs with a low risk of possible toxicity. HPV therapeutics, in particular, have benefited immensely from the growing awareness about the adverse effects of the HPV vaccine. On the other hand, the CMV therapeutics is set to witness a growing demand for CMV vaccines, leading to players operating in both markets having to establish research into both product lines. This could result in increased consolidation of the HPV and CMV therapeutics market in the coming years, as smaller players may not be able to afford developing both product lines.

Expanding Healthcare Sector in Emerging Economies to Drive Demand for HPV, CMV Therapeutics

The prime driver for the global HPV and CMV therapeutics market is the increasing prevalence of both diseases in emerging regions such as Asia Pacific and Latin America. The ongoing cultural shift in these regions has contributed to an increase in the prevalence of sexually transmitted diseases and is thus a driver for the HPV therapeutics market. Thanks to the rapid ongoing development of the healthcare sector, developing regions present lucrative opportunities for manufacturers of both HPV and CMV therapeutics. This has led to many leading market players focusing on maximizing their performance in underdeveloped/developing economies.

The increasing demand for replacements for HPV vaccines is another key driver for the global HPV therapeutics market. Digestive distress, fever, headaches, and skin irritations at the site of the injection are some of the side effects of the HPV vaccine. The growing awareness regarding the risk of the same has resulted in growing public demand for HPV therapeutics instead.

Lack of Awareness in Key Markets Hurting HPV, CMV Therapeutics Market

On the other hand, despite the advancements in the healthcare sector, the lack of awareness about the etiology and treatment of HPV and CMV is hampering the market in emerging regions, as the rate of diagnosis among patients is quite low. This is a key restraint for the HPV and CMV therapeutics market in the coming years and is likely to be ameliorated by sustained efforts from healthcare bodies as well as manufacturers of HPV and CMV therapeutics.

Download Free exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3986

Genital Warts to Remain Leading Application of HPV Therapeutics

Of the various ways in which HPV manifests, genital warts are the leading demand driver for HPV therapeutics. The high number of HPV strains that can cause genital warts, particularly when the disease is contracted through sexual contact, is responsible for the dominant share of the genital warts segment in the HPV therapeutics market.

By drug class, ganciclovir and valganciclovir dominate the demand from the CMV therapeutics market, while immunomodulators are the leading class of drugs prescribed for HPV.

Geographically, North America is the leading market for HPV and CMV therapeutics, with the regional HPV therapeutics market’s revenue expected to reach US$597.3 mn and the CMV therapeutics market’s revenue expected to reach US$202.2 mn by the end of 2016. Despite the substantial growth prospects of the Asia Pacific and Latin America markets for HPV and CMV therapeutics, the growing sexually active population and the ease of obtaining diagnostics and therapeutics in North America are likely to keep the latter dominant in the coming years.

The global markets for HPV and CMV therapeutics are expected to reach a valuation of US$2.3 bn and US$0.9 bn, respectively, by 2020. The information presented in this review is based on a Transparency Market Research report, titled, ‘Human Papillomavirus and Cytomegalovirus Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020.’

The global HPV and CMV therapeutics market is segmented as follows:

HPV Therapeutics Market, by Drug Class

Immunomodulators
Anti-neoplastic agents
Sinecatechins
Keratolytic Agents
HPV Therapeutics Market, by Application

Genital warts
Genital cancer
Oral papillomas
Epidermodysplasia verruciformis
CMV Therapeutics Market, by Drug

Val/Ganciclovir
Cidofovir
Foscarnet
CMV Therapeutics Market, by Application

CMV retinitis
Gastrointestinal ulcers
Pneumonia
Encephalitis
Others

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.